Health Care [ 12/12 ] | Pharmaceuticals [ 64/74 ]
NASDAQ | Common Stock
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform.
The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.
It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD).
The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD.
Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 8, 24 | -0.25 Decreased by -25.00% | -0.21 Decreased by -19.05% |
| May 9, 24 | -0.24 Increased by +11.11% | -0.21 Decreased by -14.29% |
| Mar 6, 24 | -0.15 Increased by +68.09% | -0.23 Increased by +34.78% |
| Nov 9, 23 | 0.07 Increased by +116.67% | -0.18 Increased by +138.89% |
| Aug 3, 23 | -0.20 Increased by +67.74% | -0.33 Increased by +39.39% |
| May 3, 23 | -0.27 Increased by +56.45% | -0.04 Decreased by -575.00% |
| Mar 22, 23 | -0.47 Increased by +22.95% | -0.41 Decreased by -14.63% |
| Nov 10, 22 | -0.42 Decreased by -250.00% | -0.50 Increased by +16.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | -7.68 M Decreased by -115.60% | -61.78 M Decreased by -951.90% | Increased by +804.85% Increased by +5.36 K% |
| Jun 30, 24 | 19.69 M Decreased by -10.92% | -32.92 M Decreased by -56.00% | Decreased by -167.19% Decreased by -75.13% |
| Mar 31, 24 | 12.54 M Decreased by -3.02% | -31.56 M Decreased by -28.68% | Decreased by -251.70% Decreased by -32.69% |
| Dec 31, 23 | 29.06 M Increased by +2.25 K% | -16.26 M Increased by +62.81% | Decreased by -55.95% Increased by +98.41% |
| Sep 30, 23 | 49.21 M Increased by +17.17 K% | 7.25 M Increased by +118.54% | Increased by +14.74% Increased by +100.11% |
| Jun 30, 23 | 22.11 M Increased by +5.79 K% | -21.10 M Decreased by -17.12 K% | Decreased by -95.47% Decreased by -388.71% |
| Mar 31, 23 | 12.93 M Increased by +638.80% | -24.52 M Increased by +34.66% | Decreased by -189.69% Increased by +91.16% |
| Dec 31, 22 | 1.24 M Decreased by -29.80% | -43.71 M Decreased by -25.65% | Decreased by -3.53 K% Decreased by -79.00% |